Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report

Int J Pharm Compd. Jul-Aug 2018;22(4):270-278.

Abstract

The ancient autoimmune skin condition psoriasis is still ubiquitous worldwide, produces the same, often-intolerable effects noted in its earliest recorded descriptions, and remains without cure. Management options designed to resolve the itchy, scaly, weeping, erythematous, and often widespread lesions of that disorder are now available, but they vary in efficacy, most are associated with the development of severe adverse effects, and many are prohibitively expensive. In this article, we describe the successful use of a compounded formulation of oral low-dose naltrexone to manage guttate psoriasis in a 75-year-old white male patient. That therapy produced only 1 adverse effect (dry skin near the lesions on the patient's arms and legs) and was relatively inexpensive. The formulation for that preparation and comments from the patient, the pharmacist who suggested its use, the prescriber, and the compounder who prepared it are included. Many clinicians are unaware of the benefits of compounded low-dose naltrexone in treating autoimmune diseases. We hope that this case report will encourage compounding pharmacists to consider and suggest it as an alternative therapy for patients who cannot tolerate or afford manufactured medications to treat psoriasis.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Drug Compounding
  • Humans
  • Male
  • Naltrexone / adverse effects
  • Naltrexone / therapeutic use*
  • Psoriasis / drug therapy*

Substances

  • Naltrexone